Blocking IL-1β to slow down progression of ALS?

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 29, 2010, Pages 12741-12742

  Van Der Meer, Jos W M ^a   Simon, Anna ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; COPPER ZINC SUPEROXIDE DISMUTASE; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; MUTANT PROTEIN; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; AUTOINFLAMMATORY DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; DISEASE COURSE; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; HUMAN; NERVE CELL DEGENERATION; NONHUMAN; NOTE; PRIORITY JOURNAL; SPINAL CORD; SURVIVAL; TREATMENT RESPONSE; ANIMAL; CHEMISTRY; CLINICAL TRIAL; ENZYMOLOGY; METABOLISM; MOUSE; PATHOLOGY;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-1BETA; MICE; MUTANT PROTEINS; SUPEROXIDE DISMUTASE;

EID: 77955630849     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1007946107     Document Type: Note

References (12)

1. Rothstein JD (2009) Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 65 (Suppl 1):S3-S9.
2. Meissner F, Molawi K, Zychlinsky A (2010) Mutant SOD1 induced IL-1β accelerates ALS pathogenesis. Proc Natl Acad Sci USA 107:13046-13050.
3. Papadimitriou D, et al. (2010) Inflammation in ALS and SMA: Sorting out the good from the evil. Neurobiol Dis 37:493-502.
4. Bartfai T, et al. (2007) Interleukin-1 system in CNS stress: Seizures, fever, and neurotrauma. Ann N Y Acad Sci 1113:173-177. (Pubitemid 350015019)
5. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519-550.
6. Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: The molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 27:621-668.
7. Friedlander RM, Brown RH, Gagliardini V, Wang J, Yuan J (1997) Inhibition of ICE slows ALS in mice. Nature 388:31.
8. Fox E, et al. (2010) The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates. J Neuroimmunol 223:138-140.
9. Gueorguieva I, et al. (2008) Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage. Br J Clin Pharmacol 65:317-325. (Pubitemid 351316912)
10. Goldbach-Mansky R, et al. (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355:581-592. (Pubitemid 44200651)
11. Opal SM, et al. (1997) Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 25:1115-1124.
12. Bodar EJ, Simon A, de Visser M, van der Meer JWM (2009) Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra). Neth J Med 67:302-305.